Search results for "lymphoma."

showing 10 items of 697 documents

Metastatic Anterior Chamber Non-Hodgkin Lymphoma in a Patient With Acquired Immunodeficiency Syndrome

1997

Purpose To alert ophthalmologists to the possibility of metastatic anterior chamber intraocular non-Hodgkin lymphoma in patients with acquired immunodeficiency syndrome (AIDS). Methods We examined a 19-year-old man with AIDS who had an anterior uveitis with pseudohypopyon and a history of 2 months of malaise. A specimen of the lesion was obtained with a 25-gauge needle for pathologic examination. RESULTS: Systemic exploration showed hepatomegaly. Abdominal computed tomography showed multiple lesions in the liver and spleen. Fine-needle aspiration disclosed a high-grade non-Hodgkin lymphoma. The result of a fine-needle aspiration obtained from a lesion in the anterior chamber was consistent …

AdultMaleAcquired Immunodeficiency SyndromePathologymedicine.medical_specialtyAnterior Chamberbusiness.industryEye NeoplasmsLymphoma Non-HodgkinEye diseaseBiopsy Needlemedicine.diseaseLymphomaMetastasisMalaiseLesionOphthalmologyImmunopathologymedicineHumansmedicine.symptombusinessComplicationUveitisAmerican Journal of Ophthalmology
researchProduct

Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hod…

2015

Aim To investigate the respective influence of software tool and total metabolic tumor volume (TMTV0) calculation method on prognostic stratification of baseline 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG-PET) in newly diagnosed Hodgkin lymphoma (HL). Methods 59 patients with newly diagnosed HL were retrospectively included. [18F]FDG-PET was performed before any treatment. Four sets of TMTV0 were calculated with Beth Israel (BI) software: based on an absolute threshold selecting voxel with standardized uptake value (SUV) >2.5 (TMTV02.5), applying a per-lesion threshold of 41% of the SUVmax (TMTV041) and using a per-patient adapted threshold based on SUVmax of the…

AdultMaleAdolescentAbsolute thresholdlcsh:MedicineGlucose-6-PhosphateStandardized uptake valueDisease-Free SurvivalPredictive Value of TestsImage Processing Computer-AssistedmedicineHumansProgression-free survivallcsh:ScienceSurvival rateAgedMultidisciplinarymedicine.diagnostic_testReceiver operating characteristicbusiness.industrylcsh:RMiddle AgedHodgkin DiseaseRadiographySurvival RatePositron emission tomographyPositron-Emission TomographyPredictive value of testsHodgkin lymphomalcsh:QFemaleNuclear medicinebusinessSoftwareResearch ArticleFollow-Up StudiesPLOS ONE
researchProduct

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct

A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus

2014

Contains fulltext : 137763.pdf (Publisher’s version ) (Open Access) Recent genome-wide association studies (GWAS) of Hodgkin lymphoma (HL) have identified associations with genetic variation at both HLA and non-HLA loci; however, much of heritable HL susceptibility remains unexplained. Here we perform a meta-analysis of three HL GWAS totaling 1,816 cases and 7,877 controls followed by replication in an independent set of 1,281 cases and 3,218 controls to find novel risk loci. We identify a novel variant at 19p13.3 associated with HL (rs1860661; odds ratio (OR)=0.81, 95% confidence interval (95% CI)=0.76-0.86, Pcombined=3.5 x 10(-10)), located in intron 2 of TCF3 (also known as E2A), a regul…

AdultMaleAdolescent[SDV]Life Sciences [q-bio]TRANSCRIPTION FACTOR E2AGENETIC-ASSOCIATIONGeneral Physics and AstronomyLocus (genetics)Genome-wide association studyHuman leukocyte antigenBiologyGeneral Biochemistry Genetics and Molecular BiologyArticleDISEASEYoung AdultBasic Helix-Loop-Helix Transcription FactorsHumansTOOLGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONEPSTEIN-BARR-VIRUSGenetic associationAgedGeneticsAged 80 and overRISKMultidisciplinaryCELL-TYPECase-control studyGenetic VariationGeneral ChemistryOdds ratioGenomicsMiddle AgedALLELESHodgkin DiseaseCANCERMalaltia de HodgkinHodgkin lymphoma (HL)GenòmicaGenetic epidemiologyCase-Control StudiesUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Hodgkin's diseaseChromosomes Human Pair 19Genome-Wide Association Study
researchProduct

Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres

1995

Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE-CytaBOM, two with MACOP-B, one with CHOP and one with LSA2-L2. As of November 1990, all newly diagnosed patients were treated with MOPP/EBV/CAD hybrid. 27 (77%) cases of ALCL CD30+ and 8 (23%) cases of Hodgkin's-related (HR) lymphoma CD30+ were diagnosed. Extranodal disease was present in 22 cases (63%), and 8 patients (23%) had primary bone marrow involvement. Twenty-three complete remissions (CR) (66%), six partial remissions (PR) (17%) and s…

AdultMaleCD30+ HODGKINS-RELATED LYMPHOMACancer Researchmedicine.medical_specialtyPathologyAdolescentCD30CHOPGastroenterologyExtranodal Diseaseimmune system diseaseshemic and lymphatic diseasesInternal medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAnaplastic large-cell lymphomaAgedbusiness.industryNON-HODGKINS LYMPHOMAMiddle Agedmedicine.diseaseLymphomaNon-Hodgkin's lymphomaSurvival RateRegimenTreatment OutcomeOncologyLymphoma Large-Cell AnaplasticFemaleANAPLASTIC LARGE CELL LYMPHOMA (CD30+/KI-1+)AGGRESSIVE CHEMOTHERAPYANAPLASTIC LARGE CELL LYMPHOMA (CD30+/KI-1+); CD30+ HODGKINS-RELATED LYMPHOMA; NON-HODGKINS LYMPHOMA; AGGRESSIVE CHEMOTHERAPYbusinessFollow-Up StudiesEuropean Journal of Cancer
researchProduct

Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

2014

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy and the fifth most common type of cancer in more developed regions of the world (1). Numerous NHL subtypes with distinct combinations of morphologic, immunophenotypic, genetic, and clinical features are currently recognized (2,3). The incidence of NHL subtypes varies substantially by age, sex, and race/ethnicity (4–7). However, the etiological implications of this biological, clinical, and epidemiological diversity are incompletely understood. The importance of investigating etiology by NHL subtype is clearly supported by research on immunosuppression, infections, and autoimmune diseases, which are the strongest and most e…

AdultMaleCancer ResearchAdolescentChronic lymphocytic leukemiaFollicular lymphomaComorbidityDiseaseNon-Hodgkin lymphoma (NHL)ArticleYoung AdultRisk Factorsimmune system diseasesOccupational Exposurehemic and lymphatic diseasesOdds RatiomedicineCluster AnalysisHumansRisk factorFamily historyLife StyleAgedAged 80 and overInternational Lymphoma Epidemiology Consortium (InterLymph)business.industryLymphoma Non-HodgkinAustraliaCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLymphomaEuropeOncologyCase-Control StudiesNorth AmericaImmunologyFemalebusinessJNCI Monographs
researchProduct

Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study.

2011

Background: Kaposi's sarcoma-associated herpes virus is associated with primary effusion lymphoma and multicentric Castleman's disease. Methods: Seropositivity to lytic and latent Kaposi's sarcoma herpes virus (KSHV) antigens were examined in 2083 lymphomas and 2013 controls from six European countries. Results: Antibodies against KSHV latent and lytic antigens were detectable in 4.5% and 3.4% of controls, respectively, and 3.6% of cases (P>0.05). The KSHV seropositivity was associated with splenic marginal zone lymphoma (SMZL) (odds ratio (OR)=4.11, 95% confidence interval (CI)=1.57–10.83) and multiple myeloma (OR=0.31, 95% CI=0.11–0.85). Conclusion: The KSHV is unlikely to contribute impo…

AdultMaleCancer ResearchAdolescentvirusesShort CommunicationserologylymphomaAntibodiesSerologyhuman herpes virus 8Young AdultHerpes virusAntigenhemic and lymphatic diseasesLymphoma Primary EffusionmedicineHumansChildKaposi's sarcomaAntigens ViralSarcoma KaposiAgedAged 80 and overbiologybusiness.industryCastleman DiseaseLymphoma Non-HodgkinCase-control studyInfant Newbornvirus diseasesInfantMiddle Agedmedicine.diseaseVirologyLymphomaEuropeOncologyLytic cycleKaposi's sarcoma-associated herpes virusCase-Control StudiesChild PreschoolImmunologyHerpesvirus 8 Humanbiology.proteinFemaleepidemiologyAntibodybusinessBritish journal of cancer
researchProduct

Identification and molecular characterization of CALM/AF10fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia

2000

The t(10;11)(p12-p13;q14-q21) observed in a subset of patients with either acute lymphoblastic leukemia or acute myeloid leukemia has been shown to result in the fusion of AF10 on chromosome 10 with CALM (also named CLTH) on chromosome 11. AF10 was originally identified as a fusion partner of MLL in the t(10;11)(p12-p13;q23) observed in myeloid leukemia. CALM is a newly isolated gene, cloned as the fusion partner of AF10 in the monocytoid cell line, U937. In order to understand the relationship between MLL, AF10, CALM and the leukemic process, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction were used to study a series of nine leukemia patients with a t…

AdultMaleCancer ResearchMyeloidOncogene Proteins FusionChromosomal translocationBiologyImmunophenotypingImmunophenotypinghemic and lymphatic diseasesAcute lymphocytic leukemiamedicineHumansCloning MolecularChildneoplasmsIn Situ Hybridization FluorescenceDNA PrimersABLBase Sequencemedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseVirologyLeukemiamedicine.anatomical_structureOncologyLeukemia MyeloidAcute DiseaseCancer researchFluorescence in situ hybridizationLeukemia
researchProduct

[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation

2003

The nucleoside 5-fluoro-2-deoxyuridine is a pyrimidine analogue accumulating in proliferative cells. We prospectively evaluated biodistribution of the PET tracer [(18)F]5-fluoro-2-deoxyuridine (FdUrd), its value for imaging malignant tumors, and its correlation to both [(18)F]2-fluoro-2-deoxyglucose (FDG)-PET findings and histological proliferation indices. In 11 previously untreated patients (5 lung carcinoma; 3 soft tissue sarcoma; 2 gastrointestinal carcinoma; 1 non-Hodgkin lymphoma [NHL]), mean doses of 290 MBq FdUrd and 390 MBq FDG were administered intravenously on subsequent days. Static PET scans were initiated 50-70 min after administration and the mean standardized uptake values (…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsProliferation indexUrinary BladderKidneyBone and BonesPyrimidine analogueFluorodeoxyglucose F18NeoplasmsmedicineCarcinomaHumansTissue DistributionRadiology Nuclear Medicine and imagingProspective StudiesAgedGastrointestinal NeoplasmsNeoplasm StagingPharmacologymedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinSoft tissue sarcomaKidney metabolismSarcomaGeneral MedicineMiddle Agedmedicine.diseaseLymphomaKi-67 AntigenLiverOncologyPositron emission tomographyFemaleSarcomaRadiopharmaceuticalsbusinessNuclear medicineCell DivisionTomography Emission-Computed
researchProduct

Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes.

2001

BACKGROUND Splenic marginal zone cell lymphoma (SMZL) is a low grade B-cell lymphoma in which patients can have circulating villous lymphocytes and can show a peculiar intrasinusoidal bone marrow (BM) infiltration. Splenectomy is the reported treatment of choice for these patients. The objective of this study was to evaluate the effects of splenectomy on patients with BM lymphomatous infiltration. METHODS BM biopsies of 16 patients with SMZL were studied morphologically and immunohistochemically. In 12 patients, BM biopsies were taken before and after splenectomy. Four patients did not undergo splenectomy, and their BM biopsies were performed with an approximately 1 year interval. RESULTS B…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentSplenectomySpleenLymphocytosisBone MarrowmedicineHumansIn patientSplenic marginal zone lymphomaAgedbusiness.industryLymphoma Non-HodgkinSplenic lymphoma with villous lymphocytesMiddle Agedmedicine.diseaseLymphomamedicine.anatomical_structureOncologySplenectomyFemaleBone marrowbusinessInfiltration (medical)Cancer
researchProduct